Real‐World Treatment Patterns and Healthcare Costs in Patients ...

Real-world treatment patterns and healthcare costs in patients with ...

This study evaluated real-world treatment patterns and associated costs in patients in the United States with psoriasis initiating systemic oral or biologic ...

Real-World Treatment Patterns and Healthcare Costs in Patients ...

Results from this real-world analysis suggest that treatment patterns and costs among patients with PsA initiating IXE are consistent with prior literature for ...

Real‐World Treatment Patterns and Healthcare Costs in Patients ...

Results from this real-world analysis suggest that treatment patterns and costs among patients with PsA initiating IXE are consistent with prior literature for ...

Real-world treatment patterns, adherence, costs, and healthcare ...

Approximately 17% (LOS: 1.4 days), 20% (LOS: 1.8 days), and 25% (LOS: 7.0 days) of patients had a hospitalization, during 1st, 2nd, and 3rd line of therapy, ...

Real-world treatment patterns and medical costs of prostate cancer ...

The share of medication costs in metPC patients was 59–63%. Table A8 in the supplementary material shows the details for each year. The mean costs per patient ...

Real-World Treatment Patterns and Healthcare Costs Among ...

The clinical burden associated with FL may also translate into a substantial economic burden. In 2 claims-based studies of commercially insured patients with FL ...

Real-World Treatment Patterns, Outcomes, Health Care Resource ...

This large population-based study found that the novel agent introduction has led to the increase of HCRU and costs of MM but was also ...

Real-world treatment patterns, healthcare resource utilisation and ...

Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a ...

RWD87 Real-World Treatment Patterns, Healthcare Costs, and ...

RWD87 Real-World Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization in Patients in the US With Metastatic Non-Small Cell Lung Cancer ...

Real-world treatment patterns, healthcare resource utilization and ...

Our study reported higher mean all-cause medical costs ($19,759 per patient per month or $237,113 per patient per year in 1L) as compared with the total medical ...

Real-World Treatment Patterns, Healthcare Resource Utilization ...

Real-world treatment patterns, healthcare resource utilization, costs, and survival among Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL).

Real-World Treatment Patterns, Healthcare Resource Utilization ...

After controlling for the baseline characteristics, the all-cause costs during the first year after the index were similar between the groups. Our all-cause ...

Real-world treatment patterns, health care resource utilization (HRU ...

Total mean PPPM healthcare costs during LOT1 was $13,589 (SD = $13,404). Conclusions: HRU and costs were high among WM pts initiating SACT. Future studies ...

PCN85 Real-World Treatment Patterns and Healthcare Costs ...

Real-world use of neoadjuvant and adjuvant chemotherapy was limited among patients with MIUC undergoing radical surgery. Metastatic disease was associated with ...

292 Real-world treatment patterns, healthcare resource use, and ...

The proportions of patients receiving monotherapy in LOT1 and LOT2 were 55.3% and 54.4%, respectively. The mean PPPM total healthcare expenditure over the ...

Real-World Treatment Patterns, Overall Survival, and Occurrence ...

The mean total per-patient-per-month cost was $11,909, with AE-related costs comprising 9% of total costs. The highest costs and survival were observed for ...

Real-World Treatment Patterns and Costs for Patients with Renal ...

Health care costs were calculated as mean daily index medication costs and as total, medical, and medication (all-cause and RCC-related) costs over the 12 ...

Real-World Treatment Patterns and Healthcare Costs Among ...

Abstract: BACKGROUND: Many patients with follicular lymphoma (FL) who receive first-line chemoimmunotherapy eventually relapse. The development of better ...

Real-World Analysis of Treatment Patterns, Healthcare Utilization ...

Conclusions: These findings, showing a high rate of mortality, a decrease in treatment duration, and an increase in costs as people progress after LOT1, add ...

Real world treatment patterns, healthcare resource utilization (HRU ...

Real world treatment patterns, healthcare resource utilization (HRU), and costs among Waldenstrom macroglobulinemia (WM) patients initiating therapy. May ...